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 Human cytomegalovirus (HCMV) infection is usually inapparent in normal 
individuals but can cause life-threatening diseases including interstitial pneumonitis, 
retinitis and meningoencephalitis in immunocompromised hosts.1 Treatment of these 
HCMV-associated diseases in immunocompromised patients frequently requires 
long-term use of antiviral agents such as ganciclovir and foscarnet, which may be 
associated with the emergence of drug-resistant HCMV strains.2 Here, we describe a 
17-year-old Japanese girl who developed refractory immune thrombocytopenic purpura 
at the age of 4 years. Despite a series of treatments including steroid, intravenous 
immunoglobulin, vincristine, vinblastine, cyclosporine, azathioprine, splenectomy, and 
rituximab, her platelet counts remained low, resulting in 2 episodes of intracranial 
hemorrhage at the age of 12 and in hemoperitoneum at the age of 13. Due to the 
immunosuppressive conditions, she developed chronic HCMV viremia and HCMV 
gastroenteritis leading to recurrent gastrointestinal bleeding at the age of 14, that 
required multiple and prolonged courses of ganciclovir therapy. At the age of 16, 
resistance to ganciclovir was clinically suspected because of persistent fever and lack of 
virologic responses, and foscarnet therapy was initiated. However, the patient showed 
continued high HCMV viral loads (>106 copies/mL) in the serum, developed fatal 
HCMV encephalitis, and died at the age of 17 despite combined use of ganciclovir and 
foscarnet as well as intravenous immune globulin. The dose of intravenous ganciclovir 
was 300 mg/day (4.5 mg/kg twice daily) at the time of cerebrospinal fluid (CSF) sample 
collection. 
There are two viral proteins involved in resistance mechanism against these 
antiviral drugs; the phosphotransferase that is encoded by UL97 and the DNA 
polymerase encoded by UL54.2 To determine the presence of drug-resistant HCMV 
strains, direct sequence analysis of these genes was performed using her various clinical 
samples (Figure).3 We found a ganciclovir-resistant UL97 mutation (C592G) and a 
foscarnet-resistant UL54 mutation (V781I) in DNA obtained from the peripheral blood, 
that were consistent with her clinical course. Interestingly, a peak of the 
foscarnet-resistant V781I mutation was shown to increase over the course of the 
treatment with foscarnet. In contrast, no mutations in both the UL97 and the UL54 
genes were demonstrated in DNA from the patient’s CSF. The CSF viral load at the time 
of drug-resistance assay was 5.0 x 107 copies/mL. Similar observations were described 
in a patient with severe combined immunodeficiency and a stem cell transplant recipient, 
both of whom were immunocompromised hosts.4, 5 One possible explanation for the 
absence of resistance mutations in the CSF is low penetration of antiviral drugs into 
CSF. Thus, continued and high-dose antiviral drug therapy may be considered for 
HCMV encephalitis even though the presence of resistance mutations in the peripheral 
compartment. These findings highlight the possibility of differential resistance to 
antiviral drugs at different sites in immunocompromised patients and the importance of 
genotypic resistance testing with various clinical samples. 
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